Luciana P F Abbade1,2,3, Silvia Regina Catharino Sartori Barraviera1,4, Maria Regina Cavariani Silvares1, Ana Beatriz B de C O Lima1, Gabriela R Haddad1, Márcia A N Gatti5, Natália Bronzatto Medolago6, Márcia Tonin Rigotto Carneiro6, Lucilene Delazari Dos Santos3,4,7, Rui Seabra Ferreira3,4,7, Benedito Barraviera1,3,4,7. 1. Department of Infectology, Dermatology, Imaging Diagnosis and Radiotherapy, Botucatu Medical School (FMB), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil. 2. Graduate Program in Nursing, Botucatu Medical School (FMB), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil. 3. Graduate Program in Clinical Research, Botucatu Medical School (FMB), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil. 4. Graduate Program in Tropical Diseases, Botucatu Medical School (FMB), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil. 5. Nursing School of Sagrado Coração University (UNISAGRADO), Bauru, Brazil. 6. Clinical Research Unit (UPECLIN), Botucatu Medical School, São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil. 7. Center for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP - Univ Estadual Paulista), Botucatu, Brazil.
Abstract
Background: Heterologous fibrin sealant (HFS) consists of a fibrinogen-rich cryoprecipitate extracted from Bubalus bubalis buffalo blood and a thrombin-like enzyme purified from Crotalus durissus terrificus snake venom. This study evaluated the safety and immunogenicity of HFS, estimated the best dose, and assessed its preliminary efficacy in the treatment of chronic venous ulcers (CVU). Methods: A phase I/II non-randomized, single-arm clinical trial was performed on 31 participants, accounting for a total of 69 active CVUs. All ulcers were treated with HFS, essential fatty acid, and Unna boot for 12 weeks. The outcomes assessed were: (1) primary safety, immunogenicity analyses, and confirmation of the lowest safe dose; (2) secondary promising efficacy by analyzing the healing process. Immunogenicity was evaluated using the serum-neutralizing (IgM and IgG) and non-neutralizing (IgA and IgE) antibody techniques against the product. The immuno-detection of IgE class antibodies was assessed using dot-blot assay before and at the end of treatment. Positive samples on dot-blot assays were subsequently analyzed by western blotting to verify the results. Results: No severe systemic adverse events related to the use of HFS were observed. Local adverse events potentially related to treatment include ulcer pain (52%), peri-ulcer maceration (16%), peri-ulcer pruritus (12%), critical colonization (8%), peri-ulcer eczema (4%), the opening of new ulcers (4%), and increased ulcerated area 4%). Neutralizing and non-neutralizing antibodies did not show significant deviations at any of the evaluated time points. Blot assays showed that all patients presented negative immunological reactions, either before or after treatment, with the thrombin-like enzyme component. In addition, two participants showed a positive immunological reaction to the cryoprecipitate component, while another two were positive before and during treatment. Regarding the secondary outcomes of preliminary efficacy, a total healing and significant reduction of the area was observed in 47.5 and 22%, respectively. A qualitative improvement was observed in the wound beds of unhealed ulcers. Conclusions: The investigational HFS bioproduct proved to be safe and non-immunogenic with a good preliminary efficacy for the treatment of CVU, according to the protocol and doses proposed. A multicentric phase III clinical trial will be necessary to verify these findings.
Background: Heterologous fibrin sealant (HFS) consists of a fibrinogen-rich cryoprecipitate extracted from Bubalus bubalis buffalo blood and a thrombin-like enzyme purified from Crotalus durissus terrificus snake venom. This study evaluated the safety and immunogenicity of HFS, estimated the best dose, and assessed its preliminary efficacy in the treatment of chronic venous ulcers (CVU). Methods: A phase I/II non-randomized, single-arm clinical trial was performed on 31 participants, accounting for a total of 69 active CVUs. All ulcers were treated with HFS, essential fatty acid, and Unna boot for 12 weeks. The outcomes assessed were: (1) primary safety, immunogenicity analyses, and confirmation of the lowest safe dose; (2) secondary promising efficacy by analyzing the healing process. Immunogenicity was evaluated using the serum-neutralizing (IgM and IgG) and non-neutralizing (IgA and IgE) antibody techniques against the product. The immuno-detection of IgE class antibodies was assessed using dot-blot assay before and at the end of treatment. Positive samples on dot-blot assays were subsequently analyzed by western blotting to verify the results. Results: No severe systemic adverse events related to the use of HFS were observed. Local adverse events potentially related to treatment include ulcer pain (52%), peri-ulcer maceration (16%), peri-ulcer pruritus (12%), critical colonization (8%), peri-ulcer eczema (4%), the opening of new ulcers (4%), and increased ulcerated area 4%). Neutralizing and non-neutralizing antibodies did not show significant deviations at any of the evaluated time points. Blot assays showed that all patients presented negative immunological reactions, either before or after treatment, with the thrombin-like enzyme component. In addition, two participants showed a positive immunological reaction to the cryoprecipitate component, while another two were positive before and during treatment. Regarding the secondary outcomes of preliminary efficacy, a total healing and significant reduction of the area was observed in 47.5 and 22%, respectively. A qualitative improvement was observed in the wound beds of unhealed ulcers. Conclusions: The investigational HFS bioproduct proved to be safe and non-immunogenic with a good preliminary efficacy for the treatment of CVU, according to the protocol and doses proposed. A multicentric phase III clinical trial will be necessary to verify these findings.
Authors: Vinícius P O Gasparotto; Fernanda C Landim-Alvarenga; Alexandre L R Oliveira; Gustavo Ferreira Simões; João F Lima-Neto; Benedito Barraviera; Rui S Ferreira Journal: Stem Cell Res Ther Date: 2014-06-10 Impact factor: 6.832
Authors: Carlos Henrique Bertoni Reis; Rogerio Leone Buchaim; Karina Torres Pomini; Abdul Latif Hamzé; Isabella Vasconcelos Zattiti; Marco Antonio Hungaro Duarte; Murilo Priori Alcalde; Benedito Barraviera; Rui Seabra Ferreira Júnior; Fenelon Martinho Lima Pontes; Carlos Roberto Grandini; Adriana de Cássia Ortiz; Simone Ortiz Moura Fideles; Renata Maria de Camargo Eugênio; Geraldo Marco Rosa Junior; Daniel de Bortoli Teixeira; Eliana de Souza Bastos Mazuqueli Pereira; João Paulo Galletti Pilon; Maria Angelica Miglino; Daniela Vieira Buchaim Journal: Polymers (Basel) Date: 2022-05-19 Impact factor: 4.967
Authors: Bruna Lopes; Patrícia Sousa; Rui Alvites; Mariana Branquinho; Ana Catarina Sousa; Carla Mendonça; Luís Miguel Atayde; Ana Lúcia Luís; Artur S P Varejão; Ana Colette Maurício Journal: Int J Mol Sci Date: 2022-01-14 Impact factor: 5.923
Authors: Simon Miguel M Lopez; Jeremey S Aguilar; Jerene Bashia B Fernandez; Angelic Gayle J Lao; Mitzi Rain R Estrella; Mark Kevin P Devanadera; Cydee Marie V Ramones; Aaron Joseph L Villaraza; Leonardo A Guevarra; Myla R Santiago-Bautista; Librado A Santiago Journal: J Venom Anim Toxins Incl Trop Dis Date: 2021-06-28